MedTrace Logo

Safety and Pharmacokinetics of Probucol and Cilostazol

NCT00549978 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-03-04

No results posted yet for this study

Summary

to investigate the safety and pharmacokinetics, in healthy adult male subjects

Conditions

  • Healthy

Interventions

DRUG

Cilostazol

cilostazol, then cilostazol/probucol

DRUG

Probucol

Probucol probucol/ cilostazol

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • In-Jin Jang, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-05-31
Completion
2008-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00549978 on ClinicalTrials.gov